BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22236417)

  • 1. [Nondetectable prostate cancer in radical prostatectomy specimens].
    Murányi M; Morshed AS; Benyó M; Tóth C; Flaskó T
    Orv Hetil; 2012 Jan; 153(3):113-7. PubMed ID: 22236417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can pT0 stage of prostate cancer be predicted before radical prostatectomy?
    Descazeaud A; Zerbib M; Flam T; Vieillefond A; Debré B; Peyromaure M
    Eur Urol; 2006 Dec; 50(6):1248-52; discussion 1253. PubMed ID: 16828964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.
    Mazzucchelli R; Barbisan F; Tagliabracci A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Virchows Arch; 2007 Apr; 450(4):371-8. PubMed ID: 17285325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Status and medicolegal implications in France pT0 stage of prostate cancer: a study by the CC-AFU].
    Bessede T; Soulié M; Mottet N; Rebillard X; Peyromaure M; Ravery V; Salomon L;
    Prog Urol; 2012 Dec; 22(16):1021-5. PubMed ID: 23178099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
    Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
    Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.
    Bessède T; Soulié M; Mottet N; Rebillard X; Peyromaure M; Ravery V; Salomon L;
    J Urol; 2010 Mar; 183(3):958-62. PubMed ID: 20083270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of radical prostatectomy for incidental carcinoma of the prostate.
    Melchior S; Hadaschik B; Thüroff S; Thomas C; Gillitzer R; Thüroff J
    BJU Int; 2009 Jun; 103(11):1478-81. PubMed ID: 19076134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.
    Köllermann J; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Hopfenmüller W; Helpap B
    Urology; 2003 Sep; 62(3):476-80. PubMed ID: 12946750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
    Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
    J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment results of radical prostatectomy in clinical stage B and C prostate cancer: comparison of the neoadjuvant therapy group versus the surgery group; retrospective analysis of 80 cases].
    Ogura Y; Sakata Y; Wakita T; Hayashi N; Hioki T; Sugimura Y
    Hinyokika Kiyo; 2003 Sep; 49(9):515-20. PubMed ID: 14598688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pT0 prostate cancer after radical prostatectomy.
    Gross JL; Masterson TA; Cheng L; Johnstone PA
    J Surg Oncol; 2010 Sep; 102(4):331-3. PubMed ID: 20589707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.